The Extremely Atypical ABT-737 Report

Other risk stratification models such as the MD Anderson prognostic score and Dusseldorf score have been published. In the only model that took karyotype into account, bone marrow blasts �� 10%, leukocyte count �� 13 �� 109 L?1, hemoglobin http://www.selleck.cn/products/Methazolastone.html with CMML based on two pivotal trials in MDS. Novel classes of agents including immunomodulatory drugs, nucleoside analogs, and small-molecule tyrosine kinase inhibitors are being investigated in the treatment of CMML. With the advent of reduced intensity conditioning, an allogeneic stem cell transplant has also become a viable option for a subset of patients. Am. J. Hematol. 87:610�C619, 2012. ? 2012 Wiley Periodicals, Inc. The 2008 World Health Organization (WHO) classification of myeloid neoplasms defines chronic myelomonocytic leukemia (CMML) as a clonal hematopoietic stem cell disorder that is characterized by the presence of an absolute monocytosis (>1 �� 109 L?1) in the peripheral blood and the presence of myelodysplastic and myeloproliferative features in the bone marrow [1]. CMML was included in the myelodysplastic syndromes (MDS) category in the http://www.selleckchem.com/products/ABT-737.html original French-American-British classification of 1982 [2]. However, there was considerable controversy as to whether it truly represented MDS or a myeloproliferative neoplasm (MPN) [3, 4]. Indeed, patients with CMML were divided into two separate categories depending on the degree of leukocytosis��CMML, MDS-type (leukocyte count ��13 �� 109 L?1) and CMML, MPN-type (leukocyte http://www.selleckchem.com/products/Nutlin-3.html count > 13 �� 109 L?1). Clinical studies with such a classification failed to provide any meaningful biologic or prognostic differences, and this classification was therefore discarded [5, 6]. In 2001, the WHO classification assigned CMML to a new category of myeloid neoplasms��the myelodysplastic/myeloproliferative (MDS/MPN) disorders [7]. Other disorders included in this category are juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia (aCML), BCR-ABL1-negative, and MDS/MPN, unclassifiable. Because the percentage of blast count was perceived to affect prognosis in patients with CMML, WHO created two separate categories among patients with CMML: (a) CMML-1 (